Though some high CBD strains are available in the New Jersey medical marijuana program, the vast majority of strains that have been tested are the THC-dominant strains which contain less than 1% CBDA. The data available from the State does not include any information on how well the different strains sell, but it can be inferred from the trend in strain types tested that the demand in the New Jersey medical market is for THC-dominant strains.
those with < 1% THCA and with CBDA concentration > 10%.
Scatter plot of THC versus THCA concentrations in strains sold in the New Jersey medicinal marijuana program. Each data point represents two values from a single strain: its concentration of Tetrahydrocannabinol (THC) and of Tetrahydrocannabinol acid (THCA). Some THC does accumulate in flower product, and in higher levels in strains that have the highest THCA concentration, though the relationship is not a liner one. In those strains in which the levels do accumulate in sufficient quantity, that quantity should be taken into account when characterizing the full cannabinoid content of strain. All measurements done by the State of New Jersey’s Public Health and Environmental Laboratories using chromatographic methods and reported as percentage by weight
In other words, consumers could be blindly choosing a product, with very little information to support their final decision.
Despite their unique and quirky street names, it appears that many strains of cannabis have virtually identical levels of THC and CBD.
Traditionally, this is thought to depend on each strain’s individual levels of tetrahydrocannabinol (THC) and cannabidiol (CBD), two major active chemical compounds found in the plant.
The marijuana industry boasts hundreds of different cannabis strains, all of which promise a unique ‘high’.
THC is regarded as the ‘psychoactive’ compound, while CBD is more about the body high – some strains are bred to have more of one and some strains have more of the other.
The authors think these newly discovered compounds, present in low quantities, could be what changes the human physiological response to the drug – and not THC and CBD as commonly thought.
What’s more, it appears that when producers try to breed highly potent strains of cannabis, they end up changing the genetic diversity of the plant and not the THC or CBD levels.
The findings show that while different levels of these compounds are being sold under different names, there is very little to distinguish them as “strains”.
“Understanding the presence of the low abundance cannabinoids could provide valuable information to the medical cannabis community,” says Mudge.